Companies press releases
CRANBURY, N.J., June 21 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results of preclinical studies in respiratory tissue with PL-3994. In rat, guinea pig and human tissues, PL-3994 produced potent relaxation of isolated airway smooth muscle, indicating that PL-3994 may be a potent bronchodilator in humans. PL-3994 is a proprietary peptide mimetic […]
CRANBURY, N.J., May 13 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics, today announced results for its third quarter ended March 31, 2010. Palatin reported a net loss of $2.0 million, or ($0.02) per basic and diluted share for the
CRANBURY, N.J., May 11 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its third quarter, fiscal year 2010 financial results on Thursday, May 13, 2010 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 13,
CRANBURY, N.J., May 4 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,709,484, titled “Substituted Melanocortin Receptor-Specific Piperazine Compounds,” today. The claims in the issued patent relate to small molecule compounds which bind to melanocortin receptors. Palatin has received Notices of Allowance
CRANBURY, N.J., March 23 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that it received $2.5 million from AstraZeneca AB pursuant to the September 2009 amendment of the exclusive research collaboration and license agreement to discover, develop and commercialize compounds that target melanocortin receptors for treatment of obesity and related indications. Payment of
Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca Read More »
CRANBURY, N.J., Feb. 25 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that it has entered into definitive agreements with certain accredited investors to sell in a registered direct offering 9.6 million units at a price of $0.27 per unit for gross proceeds of $2.6 million, before deducting placement agent fees and other
Palatin Technologies, Inc. To Raise $2.6 Million Dollars in Registered Direct Offering Read More »
CRANBURY, N.J., Feb. 16 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its second quarter ended December 31, 2009. Palatin reported net income of $4.5 million, or $0.04 per basic and diluted share, for the quarter ended December 31, 2009, compared to a net loss of $0.4 million, or $0.00 per
CRANBURY, N.J., Feb. 9 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45
Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men Read More »
